These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15198463)

  • 1. Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects?
    Voruganti LP; Awad AG
    Can J Psychiatry; 2004 May; 49(5):285-9. PubMed ID: 15198463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finger tremor and extrapyramidal side effects of neuroleptic drugs.
    Collins P; Lee I; Tyrer P
    Br J Psychiatry; 1979 May; 134():488-93. PubMed ID: 38876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic dysphoria: revisiting the concept 50 years later.
    Awad AG; Voruganti LN
    Acta Psychiatr Scand Suppl; 2005; (427):6-13. PubMed ID: 15877718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic dysphoria: towards a new synthesis.
    Voruganti L; Awad AG
    Psychopharmacology (Berl); 2004 Jan; 171(2):121-32. PubMed ID: 14647964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET examination of central D2 dopamine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs.
    Farde L; Nordström AL
    Psychopharmacol Ser; 1993; 10():94-100. PubMed ID: 8103229
    [No Abstract]   [Full Text] [Related]  

  • 7. D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects.
    Broich K; Grünwald F; Kasper S; Klemm E; Biersack HJ; Möller HJ
    Pharmacopsychiatry; 1998 Sep; 31(5):159-62. PubMed ID: 9832346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.
    Han M; Huang XF; Deng C
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):941-52. PubMed ID: 19203411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The problem of tardive akathisia.
    Gualtieri CT
    Brain Cogn; 1993 Sep; 23(1):102-9. PubMed ID: 8105819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical and legal implications of side effects from neuroleptic drugs. A round-table discussion.
    Cancro R; Davis JM; Klawans H; Tancredi L
    J Clin Psychiatry; 1981 Feb; 42(2):78-82. PubMed ID: 6109720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D2 receptor imaging and neuroleptic drug response.
    Heinz A; Knable MB; Weinberger DR
    J Clin Psychiatry; 1996; 57 Suppl 11():84-8; discussion 89-93. PubMed ID: 8941175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Testing basic visual functions in the evaluation of extrapyramidal side effects of antipsychotic agents].
    Kéri S; Antal A; Szekeres G; Szendi I; Kovács Z; Janka Z; Benedek G
    Orv Hetil; 1998 Feb; 139(5):235-8. PubMed ID: 9489377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome.
    Lee JW
    Ann Clin Psychiatry; 2007; 19(1):9-16. PubMed ID: 17453656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [D2-dopamine receptor upregulation and treatment response under neuroleptic therapy].
    Schröder J; Bubeck B; Sauer H
    Fortschr Neurol Psychiatr; 2000 Apr; 68 Suppl 1():S42-5. PubMed ID: 10907613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging.
    Voruganti L; Slomka P; Zabel P; Costa G; So A; Mattar A; Awad AG
    Neuropsychopharmacology; 2001 Nov; 25(5):642-50. PubMed ID: 11682247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal basis of neuroleptic-induced extrapyramidal side effects.
    Ossowska K
    Pol J Pharmacol; 2002; 54(4):299-312. PubMed ID: 12523484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
    Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W
    Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Extrapyramidal syndrome].
    Nakagawa S; Koyama T
    Ryoikibetsu Shokogun Shirizu; 2003; (38):179-82. PubMed ID: 12876960
    [No Abstract]   [Full Text] [Related]  

  • 19. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
    Modestin J; Wehrli MV; Stephan PL; Agarwalla P
    Schizophr Res; 2008 Mar; 100(1-3):97-107. PubMed ID: 18055180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Iatrogenic extrapyramidal disorders].
    Ludin HP
    Schweiz Med Wochenschr; 1990 Jun; 120(23):855-8. PubMed ID: 1972812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.